CM/PHR/23/5702 - NHS National Framework for Tocilizumab - March 2024
key details
| Value | £46,600,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | East Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber |
| Deadline | 3 Jan 2024 |
| Contract start | 1 Mar 2024 |
| Contract end | 28 Feb 2025 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-57b54e85-da9c-4332-bb93-8a7359735da5 |
Awards (2)
This procurement was awarded to 2 suppliers. Values shown are per-award; the notice total is £46,600,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Fresenius Kabi Limited shared | £46,600,000 | 11 Mar 2024 | active |
| Roche Products Ltd shared | £46,600,000 | 11 Mar 2024 | active |
description
Project Title: NHS National Framework for Tocilizumab - March 2024
Offer reference number: CM/PHR/23/5702
CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 8 Apr 2024 | Award (award) | · | 740537ba-c484-46a9-82ca-abe7901d188e-738925 |
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.